Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kailera TherapeuticsKLRA +2.24%11 10-Year ROIIC % is 0.00 as of Dec. 2025. GuruFocus rates KLRA with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,105 Biotechnology companies, Kailera Therapeutics ranks worse than 90497.65% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Kailera Therapeutics does not have enough data to calculate 10-Year ROIIC %.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Kailera Therapeutics 10-Year ROIIC % Related Terms
Kailera Therapeutics 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Kailera Therapeutics's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kailera Therapeutics 10-Year ROIIC % Chart
Kailera Therapeutics Annual Data
Trend
Dec24
Dec25
10-Year ROIIC %
0.00
0.00
Kailera Therapeutics Semi-Annual Data
Dec24
Dec25
10-Year ROIIC %
0.00
0.00
KLRA vs VCEL, NUVB, IOVA: 10-Year ROIIC % Comparison
For the Biotechnology subindustry, Kailera Therapeutics's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kailera Therapeutics 10-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kailera Therapeutics's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Kailera Therapeutics's 10-Year ROIIC % falls into.
Kailera Therapeutics's 10-Year ROIIC % for the quarter that ended in is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( () - () )
/
( () - () )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Kailera Therapeutics (KLRA) has a 10-Year ROIIC % of 0.00 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Kailera Therapeutics and its competitors. According to the industry distribution chart, Kailera Therapeutics ranks #999999 out of 1105 companies in the Biotechnology industry.
Is Kailera Therapeutics' 10-Year ROIIC % too high?
Kailera Therapeutics' current 10-Year ROIIC % is 0.00. Based on the distribution chart, Kailera Therapeutics ranks #999999 out of 1105 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kailera Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' 10-Year ROIIC % compare to VCEL and NUVB?
According to the Biotechnology industry distribution chart, Kailera Therapeutics ranks #999999 out of 1105 companies for 10-Year ROIIC %. This places Kailera Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Biotechnology company?
A good 10-Year ROIIC % depends on the Biotechnology industry context. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Kailera Therapeutics and its competitors. Kailera Therapeutics's current 10-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current 10-Year ROIIC % of 0.00. The current 10-Year ROIIC % is 0.00. Kailera Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current 10-Year ROIIC % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
11GF Score
Get the complete analysis for KLRA
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLRA has been successfully added to your 
